# Study of Bitopertin in Participants With EPP or XLP (APOLLO)

> **NCT06910358** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Disc Medicine, Inc** · enrollment: 183 (actual)

## Conditions studied

- Erythropoietic Protoporphyria (EPP)
- X-Linked Protoporphyria (XLP)

## Interventions

- **DRUG:** Placebo
- **DRUG:** DISC-1459

## Key facts

- **NCT ID:** NCT06910358
- **Lead sponsor:** Disc Medicine, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-04
- **Primary completion:** 2026-09
- **Final completion:** 2026-10
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06910358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06910358, "Study of Bitopertin in Participants With EPP or XLP (APOLLO)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06910358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*